Schizophrenia

NEI Schizophrenia

NEI Schizophrenia GUIDELINES app brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/364190

Contents of this Issue

Navigation

Page 8 of 19

7 Figure 1. Antipsychotic Algorithm for Schizophrenia 4-6 wk trial of another atypical or conventional antipsychotic Maintenance Phase • Suicide risk • Severe agitation or violence • Use of long-acting depots • Non-adherence • Depression or mood symptoms • Substance abuse • Prodromal or first episode psychosis is more likely to respond but can experience a greater frequency/ intensity of adverse effects • Catatonia or neuroleptic malignant syndrome (NMS) Consider at each stage: Efficacy Tolerability 6 month trial of clozapine (≤ 900 mg/day) Optimize clozapine and/or add ECT, adjunct prescription, or alternate strategies Inadequate response Inadequate response Inadequate response Intolerable movement disorder clozapine, iloperidone, or quetiapine Intolerable metabolic syndrome Intolerable sedation Adequate response First-episode schizophrenia or schizoaffective disorder 4-6 wk trial of a single atypical antipsychotic or, if not available, a trial of haloperidol, chlorpromazine, or other conventional antipsychotic LOWEST RISK: aripiprazole, lurasidone, or ziprasidone LOWER RISK: lurasidone or paliperidone ER LOWEST RISK: aripiprazole, lurasidone, or ziprasidone LOWER RISK: asenapine, iloperidone, or paliperidone ER

Articles in this issue

Archives of this issue

view archives of Schizophrenia - NEI Schizophrenia